Furthermore, we reveal intertumoral heterogeneity within pancreatic patient tumors that could tailor FAKi priming before standard-of-care chemotherapy in this disease to significantly ablate tumor progression based on Merlin status. This evidence concerns the gene NF2 and neoplasm.